Patrice Fardellone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8873286/publications.pdf

Version: 2024-02-01

56 papers

3,145 citations

147801 31 h-index 56 g-index

60 all docs

60 docs citations

60 times ranked

3658 citing authors

#	Article	IF	CITATIONS
1	Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmunity Reviews, 2010, 9, 709-715.	5.8	469
2	Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine, 2007, 74, 133-139.	1.6	168
3	2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine, 2012, 79, 304-313.	1.6	166
4	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Joint Bone Spine, 2007, 74, 440-445.	1.6	161
5	Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporosis International, 2005, 16, 1475-1480.	3.1	149
6	Presence of autoantibodies to the glycolytic enzyme \hat{l} ±-enolase in sera from patients with early rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 1196-1201.	6.7	141
7	Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?. Kidney International, 1999, 55, 2169-2177.	5.2	135
8	Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3076-3081.	3.6	119
9	Vertebral Fracture Risk Reduction With Strontium Ranelate in Women With Postmenopausal Osteoporosis Is Independent of Baseline Risk Factors. Journal of Bone and Mineral Research, 2006, 21, 536-542.	2.8	111
10	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes and Endocrinology,the, 2019, 7, 899-911.	11.4	111
11	Radiographic methods for evaluating osteoporotic vertebral fractures. Joint Bone Spine, 2009, 76, 241-247.	1.6	95
12	Clinical and laboratory safety of one year's use of acombination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: Results of a mlticenter, rndomized, double-blind, placebo-controlled study. Clinical Therapeutics, 2005, 27, 1885-1893.	2.5	85
13	Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clinical Immunology, 2007, 124, 158-164.	3.2	74
14	Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine, 2003, 70, 203-208.	1.6	65
15	Prediction of Bone Mass Density Variation by Bone Remodeling Markers in Postmenopausal Women with Vitamin D Insufficiency Treated with Calcium and Vitamin D Supplementation. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5175-5179.	3.6	65
16	Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney International, 2000, 58, 1788-1796.	5.2	62
17	Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine, 2008, 75, 303-310.	1.6	57
18	Musculoskeletal Ultrasonography in Healthy Subjects and Ultrasound Criteria for Early Arthritis (The ESPOIR Cohort). Journal of Rheumatology, 2011, 38, 613-620.	2.0	55

#	Article	IF	CITATIONS
19	Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. Journal of Rheumatology, 2007, 34, 117-22.	2.0	54
20	Effect of sex and age on the ratio of cervical to trochanteric hip fracture: A meta-analysis of 16 reports on 36,451 cases. Acta Orthopaedica, 1993, 64, 647-653.	1.4	51
21	Epidemiology of osteoporosis-related fractures in France: A literature review. Joint Bone Spine, 2010, 77, 546-551.	1.6	51
22	Prevalence and features of osteoporosis in the French general population: The Instant study. Joint Bone Spine, 2009, 76, 394-400.	1.6	49
23	The KHOALA cohort of knee and hip osteoarthritis in France. Joint Bone Spine, 2012, 79, 597-603.	1.6	48
24	Calcium intake and the risk of osteoporosis and fractures in French women. Joint Bone Spine, 2010, 77, 154-158.	1.6	45
25	Trabecular Bone Score: Where are we now?. Joint Bone Spine, 2015, 82, 320-325.	1.6	45
26	Identification of S100A9 as Biomarker of Responsiveness to the Methotrexate/Etanercept Combination in Rheumatoid Arthritis Using a Proteomic Approach. PLoS ONE, 2014, 9, e115800.	2.5	45
27	Osteoarticular side effects of BCG therapy. Joint Bone Spine, 2006, 73, 24-28.	1.6	39
28	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. Journal of Rheumatology, 2013, 40, 1650-1657.	2.0	38
29	Reproducibility of radiographic hip measurements in adults. Joint Bone Spine, 2013, 80, 52-56.	1.6	35
30	Usefulness of bone density measurement in fallers. Joint Bone Spine, 2014, 81, 403-408.	1.6	34
31	Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer. British Journal of Nutrition, 2007, 97, 611-616.	2.3	25
32	Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporosis International, 2012, 23, 1361-1369.	3.1	24
33	Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels. Annals of the Rheumatic Diseases, 2013, 72, 1032-1036.	0.9	24
34	Epistatic Interaction between BANK1 and BLK in Rheumatoid Arthritis: Results from a Large Trans-Ethnic Meta-Analysis. PLoS ONE, 2013, 8, e61044.	2.5	24
35	Predicting the fracture risk in 2008. Joint Bone Spine, 2008, 75, 661-664.	1.6	21
36	Pathophysiology and treatment of idiopathic hypercalciuria. Current Opinion in Rheumatology, 1998, 10, 373-388.	4.3	19

#	Article	IF	Citations
37	Comparative Efficacy and Safety Study of Two Chondroitin Sulfate Preparations from Different Origin (Avian and Bovine) in Symptomatic Osteoarthritis of the Knee. Open Rheumatology Journal, 2013, 7, 1-12.	0.2	19
38	Osteoporosis: Is milk a kindness or a curse?. Joint Bone Spine, 2017, 84, 275-281.	1.6	18
39	The Influence of the Definition of Patient Global Assessment in Assessment of Disease Activity According to the Disease Activity Score (DAS28) in Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2326-2328.	2.0	17
40	Nonpharmacological prevention of osteoporotic fractures. Joint Bone Spine, 2003, 70, 448-457.	1.6	16
41	Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis. Joint Bone Spine, 2010, 77, 53-57.	1.6	15
42	Prevalence of risk factors for referring post-menopausal women for bone densitometry. The INSTANT study. Joint Bone Spine, 2008, 75, 702-707.	1.6	12
43	The effect of milk consumption on bone and fracture incidence, an update. Aging Clinical and Experimental Research, 2019, 31, 759-764.	2.9	9
44	Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule. Nutrients, 2019, 11, 703.	4.1	7
45	Épidémiologie des fractures liées à l'ostéoporose en FranceÂ: revue de la littérature. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 579-585.	0.0	5
46	Exploring the treatment gap among patients with osteoporosis-related fractures in France. Archives of Osteoporosis, 2022, 17, 29.	2.4	5
47	Profile of Women Initiated on Denosumab and Pattern of Use in a Restricted Postmenopausal Osteoporosis Indication: A French Database Analysis Over the Period 2013–2014. Advances in Therapy, 2019, 36, 969-975.	2.9	4
48	Calcium, magnésium et eaux minérales naturelles. Cahiers De Nutrition Et De Dietetique, 2015, 50, S22-S29.	0.3	3
49	Ostà ©oporoseÂ: avec ou sans laitÂ?. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 334-340.	0.0	3
50	Consommation des traitements antiostéoporotiques et incidence des fractures ostéoporotiques en France entreÂ2014ÂetÂ2016Â: une prise en charge médicamenteuse insuffisante. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 387-392.	0.0	3
51	The clinical and economic burden after an osteoporosis fracture in France: a nationwide population-based study. Archives of Osteoporosis, 2021, 16, 124.	2.4	3
52	Comment évaluer le risque fracturaire en 2008. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 931-934.	0.0	2
53	Promoting the consumption of dairy products for fracture prevention: A good value for money?. Joint Bone Spine, 2018, 85, 403-404.	1.6	2
54	Reply to the correspondence by Tourtier et al. on the original article entitled â€ [*] Epidemiology of osteoporosis-related fractures in France: A literature reviewâ€ [™] . Joint Bone Spine, 2011, 78, 104.	1.6	1

#	Article	IF	CITATIONS
55	Intérêt de l'ostéodensitométrie chez les sujets chuteurs. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 297-302.	0.0	1
56	Apport de calcium et risque d'ostéoporose et de fractures chez les femmes françaises. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 182-187.	0.0	0